Laparoscopy for Benign Colorectal Diseases
Clinics in Colon and Rectal Surgery 2010; 23: 042-050DOI: 10.1055/s-0030-1247857ABSTRACTThe applicability of laparoscopy to many complex intraabdominal colorectal procedures continues to expand, and has been shown to be feasible and safe in experienced hands. Data are available on the elderly, rectal prolapse, diverticulitis, Hartman's takedown, small bowel obstruction, Crohn's disease, and ulcerative colitis. Clinically relevant advantages have been clearly demonstrated in selected patient populations. Laparoscopic surgery for benign colorectal disease should be considered in patients suitable for this approach to an abdominal operation.[...]© Thieme Medical PublishersGet connected:Table of contents | Abstract | Full text (Source: Clinics in Colon and Rectal Surgery)...
POSTED 03/10/2010 at 11:13 AM --
|
National Event Addresses Breakthroughs in Crohn’s & Colitis Research: National Expert & Researcher Answers Key Questions on Interactive Webcast/Teleconference
Research in inflammatory bowel diseases (IBD) is changing and improving the way Crohn’s disease and ulcerative colitis—chronic and often debilitating digestive diseases impacting 1.4 million Americans—are diagnosed and treated. On Tuesday, March 30, at 1 PM ET , Crohn’s and colitis patients, families, and caregivers can tune into a Crohn’s & Colitis Foundation of America (CCFA) interactive educational webcast/teleconference entitled, “Breakthroughs in IBD Research: Helping You Today.” National expert and researcher Stephan R. Targan, MD, Director of the Inflammatory Bowel and Immunobiology Research Institute at Cedars-Sinai Medical Center, will discuss recent advances in IBD research and answer audience questions during an interactive question ......
POSTED 03/10/2010 at 10:45 AM --
|
Potty Training
Title: Potty TrainingCategory: Health and LivingCreated: 3/10/2010 10:12:00 AMLast Editorial Review: 3/10/2010 10:12:51 AM (Source: MedicineNet Crohn's Disease General)...
POSTED 03/10/2010 at 01:00 AM --
|
N-3 polyunsaturated fatty acid diet therapy for patients with inflammatory bowel disease
N-3 polyunsaturated fatty acids (PUFA) are considered important pharmaconutrients for modulating mucosal immunity and therapeutic responses in patients with inflammatory bowel disease (IBD). We investigated the influence of diet therapy involving the use of an "n-3 PUFA food exchange table" (n-3DP) on the fatty acid composition of the erythrocyte membranes of IBD patients and its remission-maintaining effects.We analyzed the fatty acid composition of the erythrocyte membrane before and after n-3DP intervention in 20 initial-onset IBD patients who had not undergone any dietary intervention. We then analyzed it again and evaluated disease activity after 12-18 months intervention in 230 IBD patients (168 ulcerative colitis, 62 Crohn's disease; follow-up group) in whom n-3DP was introduced aft......
POSTED 03/09/2010 at 06:00 PM --
|
Overexpression of translocator protein in inflammatory bowel disease: Potential diagnostic and treatment value
Inflammatory bowel diseases (IBDs), such as ulcerative colitis and Crohn's disease, are chronic inflammatory disorders that increase the risk for colorectal cancer. The mitochondrial translocator protein (TSPO) is a high-affinity drug- and cholesterol-binding protein expressed in the colon and its expression is increased in colon cancers. The aim of this study was to investigate TSPO expression in IBD biopsies and to establish an animal model of IBD to examine the role of TSPO. In addition, we evaluated the potential use of TSPO drug ligands in diagnosing and treating IBD.TSPO expression in IBD biopsies was evaluated using immunohistochemistry. IBD was induced in a rat experimental model via treatment with dextran sodium sulfate (DSS). Colon morphology, TSPO expression, and proinflammatory......
POSTED 03/09/2010 at 06:00 PM --
|
IL-23/IL-17 axis in IBD
Abstract: Gut inflammation occurring in patients with Crohn's disease and patients with ulcerative colitis has been traditionally associated with an exaggerated Th1 or Th2 cell response, respectively. However, recent studies have shown that in both inflammatory bowel diseases (IBD) there is also enhanced synthesis of cytokines made by a distinct subset of T helper cells, termed Th17 cells. The discovery that this new T-cell subset drives immune-mediated pathology in the gut, and that interleukin (IL)-23 amplifies Th17 cell responses and gut inflammation, has contributed to elucidate new pathways of tissue damage as well as to open new avenues for development of therapeutic strategies in IBD. Nonetheless, it has been recently shown that Th17-related cytokines, such as IL-17A and IL-22, can ......
POSTED 03/09/2010 at 06:00 PM --
|
Population-Specific Susceptibility to Crohn's Disease and Ulcerative Colitis; Dominant and Recessive Relative Risks in the Japanese Population
Crohn's disease (CD), a type of chronic inflammatory bowel disease (IBD), is commonly found in European and East Asian countries. The calculated heritability of CD appears to be higher than that of ulcerative colitis (UC), another type of IBD. Recent genome-wide association studies (GWAS) have identified more than thirty CD-associated genes/regions in the European population. In the East Asian population, however, a clear association between CD and an associated gene has only been detected with TNFSF15. In order to determine if CD susceptibility differs geographically, nine SNPs from seven of the European CD-associated genomic regions were selected for analysis. The genotype frequencies for these SNPs were compared among the 380 collected Japanese samples, which consisted of 212 IBD cases ......
POSTED 03/09/2010 at 06:00 PM --
|
Fibrin Glue Heals Perianal Fistulas
Fibrin glue improves perianal fistula healing in patients with Crohn's disease, French researchers have found. Reuters Health Information (Source: Medscape Gastroenterology Headlines)...
POSTED 03/09/2010 at 12:34 PM --
|
Crohn's disease: Why I won't let it control my life
MUSICIAL Rick Parfitt Jnr, 35, the son of Status Quo's legendary rocker, talks about the illness he has battled since childhood and why he has now helped set up his own charity to try to find a cure. (Source: Daily Express - Health)...
POSTED 03/08/2010 at 06:00 PM --
|
Colonoscopy in Hong Kong Chinese children.
CONCLUSION: Colonoscopy is a safe procedure in our Chinese children. The increasing diagnosis of IBD in recent decades may reflect a rising incidence of the disease in our children.
PMID: 20205284 [PubMed - in process] (Source: World Journal of Gastroenterology : WJG)...
POSTED 03/06/2010 at 06:00 PM --
|
Nod proteins link bacterial sensing and autophagy.
Authors: Travassos LH, Carneiro LA, Girardin S, Philpott DJ
Autophagy is one of the main cellular degradation systems in eukaryotes, responsible for the elimination of long-lived proteins and damaged organelles. Besides its well-documented role as a housekeeping mechanism, autophagy has recently caught the attention of groups working in the fields of microbiology and immunology, especially those working in innate immunity. In particular, the highly specific segregation and degradation of intracellular bacteria by the autophagic machinery was a matter of great interest. However, it was still unclear how the autophagy machinery could target intracellular bacteria with such specificity. We have recently analyzed the role of the intracellular peptidoglycan (PG) receptors Nod1 and Nod2 as a......
POSTED 03/06/2010 at 09:52 AM --
|
Crohn's disease - infliximab (review) and adalimumab: final appraisal determination
(Source: NHS Evidence - Gastroenterology and liver diseases - News)...
POSTED 03/06/2010 at 08:11 AM --
|
Long-term outcome of endoscopic dilatation in patients with Crohn's disease is not affected by disease activity or medical therapy
Conclusion
This largest series ever reported confirms that long term efficacy of endoscopic dilatation of Crohn's disease outweighs the complication risk. Neither active disease at the time of dilatation nor medical therapy afterwards predict recurrent dilatation or surgery. (Source: Gut)...
POSTED 03/05/2010 at 05:12 AM --
|
Management of Crohn's disease
(Source: Gut)...
POSTED 03/05/2010 at 05:12 AM --
|
Long-term value of endoscopic dilatation for Crohn's strictures
(Source: Gut)...
POSTED 03/05/2010 at 05:12 AM --
|
Gene Sequencing Yields Picture of Human Gut
Title: Gene Sequencing Yields Picture of Human GutCategory: Health NewsCreated: 3/4/2010 2:10:00 PMLast Editorial Review: 3/5/2010 (Source: MedicineNet Crohn's Disease General)...
POSTED 03/05/2010 at 01:00 AM --
|
Health Tip: What's Lactose Intolerance?
Title: Health Tip: What's Lactose Intolerance?Category: Health NewsCreated: 3/5/2010 10:10:00 AMLast Editorial Review: 3/5/2010 (Source: MedicineNet Crohn's Disease General)...
POSTED 03/05/2010 at 01:00 AM --
|
NICE Recommends Infliximab And Adalimumab For The Treatment Of Severe, Active Crohn's Disease
In final draft guidance published today (4 March) NICE has recommended infliximab and adalimumab as treatment options for people with severe, active Crohn's disease whose condition has not responded to conventional therapy, or who are intolerant of or have contraindications to conventional therapy. Crohn's disease is a chronic inflammatory condition of unknown cause affecting the gastrointestinal tract (gut). It is estimated that around 60,000 people in the UK have the disease, with approximately 3,000 (5%) having the most severe forms of the condition... (Source: Health News from Medical News Today)...
POSTED 03/04/2010 at 07:00 PM --
|
NICE Recommends Infliximab And Adalimumab For The Treatment Of Severe, Active Crohn's Disease
In final draft guidance published today (4 March) NICE has recommended infliximab and adalimumab as treatment options for people with severe, active Crohn's disease whose condition has not responded to conventional therapy, or who are intolerant of or have contraindications to conventional therapy... (Source: Crohn's News From Medical News Today)...
POSTED 03/04/2010 at 07:00 PM --
|
NICE sets out Crohn's drug choices
People with chronic Crohn's disease, especially those who have not responded to conventional therapy, should be treated with infliximab or adalimumab, the National Institute for Clinical Excellence (NICE) has recommended. (Source: Pharmacy Europe)...
POSTED 03/04/2010 at 08:18 AM --
|
